Connect Capital Lease Obligations from 2010 to 2025
| CNTB Stock | USD 0.68 0.08 10.53% |
Capital Lease Obligations | First Reported 2010-12-31 | Previous Quarter 534.8 K | Current Value 508 K | Quarterly Volatility 569.7 K |
Check Connect Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Connect Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 20.2 K, Other Operating Expenses of 76.5 M or Tax Provision of 131.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.61. Connect financial statements analysis is a perfect complement when working with Connect Biopharma Valuation or Volatility modules.
Connect | Capital Lease Obligations |
Latest Connect Biopharma's Capital Lease Obligations Growth Pattern
Below is the plot of the Capital Lease Obligations of Connect Biopharma Holdings over the last few years. Connect Biopharma capital lease obligations are the amount due for long-term lease agreements that are nearly equivalent to Connect Biopharma asset purchases. For example, Connect Biopharma can use a capital lease to finance the purchase of an asset without ever buying it. A capital lease gives companies such as Connect Biopharma control over an asset for a big portion of its life. It is the total obligations of a company under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. Connect Biopharma's Capital Lease Obligations historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Connect Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Capital Lease Obligations | 10 Years Trend |
|
Capital Lease Obligations |
| Timeline |
Connect Capital Lease Obligations Regression Statistics
| Arithmetic Mean | 939,485 | |
| Geometric Mean | 852,700 | |
| Coefficient Of Variation | 60.64 | |
| Mean Deviation | 257,314 | |
| Median | 882,000 | |
| Standard Deviation | 569,667 | |
| Sample Variance | 324.5B | |
| Range | 2.5M | |
| R-Value | 0.05 | |
| Mean Square Error | 346.9B | |
| R-Squared | 0 | |
| Significance | 0.86 | |
| Slope | 5,684 | |
| Total Sum of Squares | 4.9T |
Connect Capital Lease Obligations History
About Connect Biopharma Financial Statements
Connect Biopharma stakeholders use historical fundamental indicators, such as Connect Biopharma's Capital Lease Obligations, to determine how well the company is positioned to perform in the future. Although Connect Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Connect Biopharma's assets and liabilities are reflected in the revenues and expenses on Connect Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Connect Biopharma Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Lease Obligations | 534.8 K | 508 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Connect Biopharma Correlation against competitors. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.